- Home
- TWST
as 07-26-2024 4:00pm EST
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of its revenue from the United States.
Upcoming Earnings Alert:
Get ready for potential market movements as Twist Bioscience Corporation TWST prepares to release earnings report on 02 Aug 2024.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 2.8B | IPO Year: | 2018 |
| Target Price: | $49.75 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.36 | EPS Growth: | N/A |
| 52 Week Low/High: | $14.42 - $60.90 | Next Earning Date: | 08-02-2024 |
| Revenue: | $277,486,000 | Revenue Growth: | 21.79% |
| Revenue Growth (this year): | 26.28% | Revenue Growth (next year): | 20.27% |
Stock Insider Trading Activity of Twist Bioscience Corporation (TWST)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Finn Patrick John | TWST | President and COO | Jul 23 '24 | Sell | $56.63 | 2,207 | $124,971.38 | 171,212 | SEC Form 4 |
| Laponis Adam | TWST | Chief Financial Officer | Jul 9 '24 | Sell | $48.91 | 842 | $41,184.75 | 73,602 | SEC Form 4 |
| Finn Patrick John | TWST | President and COO | Jul 2 '24 | Sell | $48.00 | 476 | $22,848.95 | 173,419 | SEC Form 4 |
| Leproust Emily M. | TWST | Chief Executive Officer | Jul 2 '24 | Sell | $48.00 | 1,114 | $53,474.23 | 504,732 | SEC Form 4 |
| Cho Dennis | TWST | See Remarks | Jul 2 '24 | Sell | $48.00 | 126 | $6,048.25 | 79,705 | SEC Form 4 |
| Green Paula | TWST | SVP of Human Resources | Jun 20 '24 | Sell | $49.41 | 297 | $14,674.77 | 90,296 | SEC Form 4 |
| Leproust Emily M. | TWST | Chief Executive Officer | Jun 20 '24 | Sell | $49.41 | 1,732 | $85,578.12 | 505,846 | SEC Form 4 |
| Cho Dennis | TWST | See Remarks | Jun 14 '24 | Sell | $51.04 | 95 | $4,848.41 | 80,065 | SEC Form 4 |
| Cho Dennis | TWST | See Remarks | Jun 6 '24 | Sell | $51.33 | 276 | $14,166.80 | 80,160 | SEC Form 4 |
| WERNER ROBERT F. | TWST | Chief Accounting Officer | Jun 6 '24 | Sell | $51.33 | 242 | $12,421.62 | 39,945 | SEC Form 4 |
| Green Paula | TWST | SVP of Human Resources | Jun 6 '24 | Sell | $51.33 | 918 | $47,120.02 | 90,593 | SEC Form 4 |
| Leproust Emily M. | TWST | Chief Executive Officer | Jun 6 '24 | Sell | $51.33 | 2,408 | $123,600.23 | 507,578 | SEC Form 4 |
| WERNER ROBERT F. | TWST | Chief Accounting Officer | May 23 '24 | Sell | $42.32 | 3,361 | $142,244.24 | 40,187 | SEC Form 4 |
| Green Paula | TWST | SVP of Human Resources | May 3 '24 | Sell | $37.13 | 910 | $33,791.94 | 91,511 | SEC Form 4 |
| Leproust Emily M. | TWST | Chief Executive Officer | May 3 '24 | Sell | $37.13 | 4,163 | $154,588.84 | 509,986 | SEC Form 4 |
| Cho Dennis | TWST | See Remarks | May 3 '24 | Sell | $37.13 | 568 | $21,092.11 | 80,436 | SEC Form 4 |
| WERNER ROBERT F. | TWST | Chief Accounting Officer | May 3 '24 | Sell | $37.13 | 132 | $4,901.69 | 43,548 | SEC Form 4 |
| Finn Patrick John | TWST | President and COO | May 3 '24 | Sell | $37.13 | 2,311 | $85,816.67 | 173,895 | SEC Form 4 |
| Banyai William | TWST | See Remark | May 3 '24 | Sell | $37.13 | 798 | $29,632.93 | 345,188 | SEC Form 4 |
| Finn Patrick John | TWST | President and COO | Apr 23 '24 | Sell | $30.12 | 2,174 | $65,483.05 | 176,206 | SEC Form 4 |
| Laponis Adam | TWST | Chief Financial Officer | Apr 9 '24 | Sell | $33.16 | 556 | $18,434.18 | 74,444 | SEC Form 4 |
| Cho Dennis | TWST | See Remarks | Apr 2 '24 | Sell | $32.74 | 129 | $4,222.94 | 81,004 | SEC Form 4 |
| Banyai William | TWST | See Remark | Apr 2 '24 | Sell | $32.74 | 327 | $10,704.67 | 345,986 | SEC Form 4 |
| Finn Patrick John | TWST | President and COO | Apr 2 '24 | Sell | $32.74 | 492 | $16,106.11 | 178,380 | SEC Form 4 |
| Leproust Emily M. | TWST | Chief Executive Officer | Apr 2 '24 | Sell | $32.74 | 1,132 | $37,057.15 | 514,149 | SEC Form 4 |
Latest Twist Bioscience Corporation News
TWST Breaking Stock News: Dive into TWST Ticker-Specific Updates for Smart Investing
Zacks
11 hours ago
Twist Bioscience (TWST) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Zacks
4 days ago
Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
Business Wire
9 days ago
Twist Bioscience Announces Clinical Progression of Pure Biologics’ Antibody Candidate Discovered Using Twist’s Antibody Libraries
Zacks
12 days ago
Take the Zacks Approach to Beat the Markets: NVIDIA, Twist Bioscience, Ollie's Bargain Outlet in Focus
Business Wire
16 days ago
Twist Bioscience to Report Fiscal 2024 Third Quarter Financial Results on Friday, August 2, 2024
Business Wire
17 days ago
Twist Bioscience Expands High-Throughput IgG Antibody Portfolio with Launch of CHO Express Antibodies
MT Newswires
17 days ago
Goldman Sachs Raises Price Target on Twist Bioscience to $55 From $45, Maintains Buy Rating
MT Newswires
17 days ago
Twist Bioscience Launches Synthetic RNA Control for H5N1 Influenza A
Compare TWST vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TWST Twist Bioscience Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.